Recent Updates
Recently added Catalysts
RVTY Positive Sentiment

Revvity to Present at Upcoming Investor Conferences

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Revvity, Inc. has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The presentations will feature key executives, highlighting the company's commitment to investor relations and transparency. These events are scheduled for September 2026.
Price reaction · baseline $116.02 (2026-08-10 close) · hit pre-market · clean, no other RVTY news in the window
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Revvity is actively engaging with investors.
  • The company is participating in multiple high-profile conferences.
  • Leadership presence at these events showcases confidence.

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird’s 2026 Global Healthcare Conference Tuesday, September

Frequently Asked Questions

When is Revvity presenting at the Wells Fargo Conference?

Revvity will present at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026.

Who will represent Revvity at the Morgan Stanley Conference?

Max Krakowiak, senior vice president and chief financial officer, will represent Revvity.

What is the date of Baird's 2026 Global Healthcare Conference?

The date for Baird's 2026 Global Healthcare Conference is September 14, 2026.

ShareAdd on Google
Tags: RVTY Revvity investor conferences Wells Fargo Morgan Stanley healthcare
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$1023M liquidity · $0M/mo burn
Low dilution risk